Conference about Orphan Medicinal Product Designation in the EU

Website http://bit.ly/Orphan-Medicinal-Product-Designation-in-the-EU | Edit Freely

Category Medicinal; Product Designation; EU; Medicinal Product

Deadline: February 04, 2016 | Date: February 05, 2016

Venue/Country: Online Event, U.S.A

Updated: 2016-01-04 14:51:08 (GMT+9)

Call For Papers - CFP

The European Medicines Agency plays a central role in the development and authorization of medicines for rare diseases. These medicines are termed ‘orphan medicines’ in the medical world.

It is estimated that today in the EU, 5-8000 distinct rare diseases affect 6-8% of the population - about 30 million people. Rare diseases are defined as life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in EU. This is equivalent to around 250,000 people or less for each disease. These conditions occur so infrequently that the cost of developing and bringing to the market a medicinal product to diagnose, prevent or treat the condition would not be recovered by the expected sales of the medicinal product. Patients suffering from rare conditions should be entitled to the same quality of treatment as other patients.

Why should you Attend:

Orphan medicinal products are intended for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect no more than 5 in 10,000 people in the European Union.

Designation as an orphan medicinal product in the EU has important advantages. Sponsors who obtain orphan designation benefit from a number of incentives, including protocol assistance, a type of scientific advice specific for designated orphan medicines, fee waivers or reductions for the regulatory procedures or a 10 year market exclusivity once the medicine is on the market. Therefore, it is important for companies to know the process for designation.

In this Webinar the process for obtaining designation is explained in detail. There are many factors to consider when preparing an application, and taking those into account will ensure a smooth process. The main factors to consider are:

Definition of a medical condition

Dealing with subsets

How to show significant benefit

Areas Covered in the Session:

Legal background

The COMP

Criteria for designation

How to describe the medical condition

How to deal with subsets

Significant benefit

Timing of designation

Procedure for obtaining designation

Guidelines for Marketing Authorization procedures

Determinants for successful Marketing Authorizations

Who Will Benefit:

Regulatory Affairs personnel

Senior management

Project Managers

Medical writers

CRAs and CRCs

QA / Compliance personnel

Investigators

Clinical Research Scientists

QA / QC Auditors and Staff

Consultants

Speaker Profile:

Adriaan Fruijtier has graduated as a pharmacist at the University of Utrecht, The Netherlands.

He is currently Director Regulatory Affairs at CATS Consultants. Until March 2004 he has been Head of the Oncology Group within Global Regulatory Affairs at Bayer AG, Wuppertal, Germany, and Bayer Corporation, West Haven, CT, USA. Between 2001 and 2003 he was Director of Regulatory Affairs at Micromet AG, a biotech company in Munich, Germany. Prior to joining Micromet he has worked during four years as a Project Manager for Oncology Projects at the European Medicines Agency in London, United Kingdom.

Contact Detail:

NetZealous - Compliance4All,

161 Mission Falls Lane, Suite 216,

Fremont, CA 94539, USA.

Phone: +1-800-447-9407

Email: supportcompliance4All.com

http://www.compliance4all.com/

Event Link : http://bit.ly/Orphan-Medicinal-Product-Designation-in-the-EU